Dr. Shunji Tomatsu M.D. Ph.D.
Chief Medical Advisor
Nemours Biomedical Research
Principal Research Scientist, Orthopedics
Director of the Skeletal Dysplasia Lab in the Center for Orthopedic Research and Development (CORD)
1600 Rockland Rd.,Wilmington, DE. 19899-0269
Cell: 314-691-0430, Office Tel: 314-691-0430
E-mail: tomatsushunji@gmail.com, stomatsu@nemours.org
Dr. Michael Beck
Head of Center for Lysosomal Storage Disorders
Children’s Hospital University of Mainz
Department of Pediatrics
Langenbeckstrasse 1 Mainz, D55131
Germany
e-mail: beck@kinder.klinik.uni-mainz.de
Prof. Luis A. Barrera
Pontificia Universidad Javeriana
Carrera 7 No. 43-82
Edificio Jesus Emilio Rameritz (53)
Bogota D.C., Colombia
e-mail: abarrera@javeriana.edu.co
Professor Tadao Orii
Emirtus Professor of Gifu University, School of Medicine Head, Japanese Society for Research of Mucoplysacchridoses
40 Tsukasamachi -
Gifu-shi
Gifu, Japan 500
e-mail: tadaorii@aqua.ocn.ne.jp |
Joseph Muenzer, MD, Ph.D
Associate Professor of Pediatrics
Department of Pediatrics
Division of Genetics and Metabolism
University of North Carolina at Chapel Hill
642 Burnett-Womack, CB#7487
Chapel Hill, NC 27599-7487
Tel: 919-966-1447
Fax: 919-966-9042
E-mail: muenzer@med.unc.edu
Professor Roberto Giugliani, MD, PhD
Medical Genetics Service
Hospital de Clinicas de Porto Alegre
Rua Ramiro Barcelos, 2350
90035-903 Porto Alegre - RS
Brazil
tel + 55 51 33598011
fax + 55 51 33598010
e-mail: rgiugliani@hcpa.ufrgs.br
Dr. Maurizio Scarpa
Department of Pediatrics
University of Padova
Via Giustiniani 3
I-35128 Padova Italy
e-mails: scarpa@child.pedi.unipd.it scarpa@pediatria.unipd.it
The International Morquio Organization will ask the Medical advisors the following major roles on behalf of Morquio families and societies:
1.Consultation with Morquio Families on any Morquio related issues: those discussions between families and doctors may be issued in the newsletter as a question and answer column.
2.Assessment to a new drug or treatment in addition to existing treatments such as surgical operations and oral medications and introduction of those therapies to the families.
3.Communication and support with the pharmaceutical companies and other third parties for the funding, publication, and agreement. |
